[go: up one dir, main page]

MX2021010058A - Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. - Google Patents

Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.

Info

Publication number
MX2021010058A
MX2021010058A MX2021010058A MX2021010058A MX2021010058A MX 2021010058 A MX2021010058 A MX 2021010058A MX 2021010058 A MX2021010058 A MX 2021010058A MX 2021010058 A MX2021010058 A MX 2021010058A MX 2021010058 A MX2021010058 A MX 2021010058A
Authority
MX
Mexico
Prior art keywords
skin disorders
treating facial
rapamycin formulations
topical rapamycin
facial angiofibromas
Prior art date
Application number
MX2021010058A
Other languages
English (en)
Inventor
Paul Beckett
Henri Lichenstein
Tian Xu
Jonathan M Rothberg
Jeff Grotzke
Keith Fandrick
Original Assignee
Ai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Therapeutics Inc filed Critical Ai Therapeutics Inc
Publication of MX2021010058A publication Critical patent/MX2021010058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación proporciona composiciones de gel de rapamicina para administración tópica y composiciones y métodos relacionados que incluyen su uso en el tratamiento de una afección, enfermedad o trastorno de la piel.
MX2021010058A 2019-02-20 2020-02-19 Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. MX2021010058A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962807786P 2019-02-20 2019-02-20
US201962835630P 2019-04-18 2019-04-18
PCT/US2020/018816 WO2020172266A1 (en) 2019-02-20 2020-02-19 Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Publications (1)

Publication Number Publication Date
MX2021010058A true MX2021010058A (es) 2021-11-12

Family

ID=70009373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010058A MX2021010058A (es) 2019-02-20 2020-02-19 Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.

Country Status (12)

Country Link
US (1) US20200261427A1 (es)
EP (1) EP3927319A1 (es)
JP (1) JP2022521006A (es)
KR (1) KR20210130769A (es)
CN (1) CN113710232A (es)
AU (1) AU2020226527A1 (es)
BR (1) BR112021016296A2 (es)
CA (1) CA3131232A1 (es)
IL (1) IL285715A (es)
MX (1) MX2021010058A (es)
TW (1) TW202045165A (es)
WO (1) WO2020172266A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200069661A1 (en) * 2018-08-30 2020-03-05 Chemistryrx Sirolimus containing compositions
CN113453758A (zh) * 2019-02-27 2021-09-28 国立大学法人大阪大学 脉管异常治疗用外用剂
TWI871406B (zh) * 2019-12-26 2025-02-01 日商參天製藥股份有限公司 含西羅莫司(sirolimus)或其鹽之水性懸浮組合物
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition
CN113332228B (zh) * 2021-04-29 2023-03-31 杭州中美华东制药有限公司 一种西罗莫司凝胶制剂
AU2022300265A1 (en) * 2021-06-21 2024-01-18 Palvella Therapeutics, Inc. Methods and compositions for treating gorlin syndrome
EP4401730A4 (en) * 2021-09-15 2025-07-30 Palvella Therapeutics Inc RAPAMYCIN COMPOSITIONS AND THEIR USE IN THE TREATMENT OF MICROKYSTIC LYMPHATIC MALFORMATION
CN119698280A (zh) * 2022-08-12 2025-03-25 国立大学法人群马大学 用于治疗系统性硬皮病中的皮肤硬化的包含西罗莫司的皮肤外用药
CN116509849B (zh) * 2023-05-26 2025-01-24 首都医科大学附属北京儿童医院 雷帕霉素在制备辅助治疗咖啡斑药物中的应用
AU2023203871B1 (en) * 2023-06-20 2024-07-25 Aft Pharmaceuticals Ltd A Rapamycin Method of Treatment and Composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US7169594B2 (en) 2002-08-12 2007-01-30 Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
AU2006218918A1 (en) 2005-03-02 2006-09-08 Wyeth Purification of rapamycin
DK1983984T3 (en) 2006-02-02 2018-06-14 Novartis Ag Treatment of tuberous sclerosis
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US20120022095A1 (en) 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
NO2444068T3 (es) * 2010-10-21 2014-12-20
WO2012105521A1 (ja) * 2011-01-31 2012-08-09 国立大学法人大阪大学 皮膚疾患を処置するための外用薬およびその製造方法
WO2012142145A1 (en) 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
US10172789B2 (en) * 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
HUP1400075A2 (hu) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
KR102638112B1 (ko) * 2015-02-02 2024-02-20 산텐 세이야꾸 가부시키가이샤 폴리아프론 및 이의 안검 투여
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
KR20190039220A (ko) 2016-08-10 2019-04-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 국소적 라파마이신 요법

Also Published As

Publication number Publication date
JP2022521006A (ja) 2022-04-04
KR20210130769A (ko) 2021-11-01
IL285715A (en) 2021-10-31
CN113710232A (zh) 2021-11-26
BR112021016296A2 (pt) 2021-11-09
WO2020172266A9 (en) 2020-10-22
TW202045165A (zh) 2020-12-16
WO2020172266A1 (en) 2020-08-27
EP3927319A1 (en) 2021-12-29
AU2020226527A1 (en) 2021-10-14
CA3131232A1 (en) 2020-08-27
US20200261427A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2021002321A (es) Nuevos metodos.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
EP4338804A3 (en) Epinephrine spray formulations
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
WO2016043874A3 (en) Combination therapy for treating cancer
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
EP3922297A4 (en) DEVICE FOR SKIN CARE, COSMETICS AND MEDICAL TREATMENT
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
MX2020007062A (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.